高级检索
当前位置: 首页 > 详情页

The long-term survival of esophageal cancer in elderly patients: A multi-center, retrospective study from China

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Chinese Acad Sci, Univ Chinese Acad Sci, Zhejiang Canc Hosp,Zhejiang Key Lab Diag & Treatm, Canc Hosp,Inst Basic Med & Canc IBMC,Dept Canc Pr, Hangzhou 310022, Zhejiang, Peoples R China [2]Hebei Med Univ, Hosp 4, Tumor Hosp Hebei Prov, Canc Inst, Shijiazhuang, Hebei, Peoples R China [3]Henan Canc Hosp, Zhengzhou, Henan, Peoples R China [4]Peking Univ, Beijing Canc Hosp, Canc Hosp, Beijing, Peoples R China [5]Hubei Canc Hosp, Wuhan, Peoples R China [6]Zhongshan City Peoples Hosp, Canc Inst, Zhongshan, Guangdong, Peoples R China [7]Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Natl Canc Ctr, Beijing 100021, Peoples R China
出处:
ISSN:

关键词: clinical risk factors elderly patient epidemiology esophageal cancer survival

摘要:
Background Esophageal cancer (EC) often occurs in the elderly, and approximately 40% of patients are 70 years or older. To investigate the long-term survival of EC in elderly patients, to provide a theoretical direction for better management and predicting survival of EC based on the hospital-based multi-center study in China. Methods The study was conducted in 18 hospitals including 6 provincial hospitals, 8 municipal hospitals, and 4 county hospitals. We extracted information from medical record homepage, records of admission and discharge, and pathological diagnosis reports from the medical record department of the elderly patients at 70-84 years old to obtain the 3-year and 5-year overall survival (OS), and main associated factors, and to analyze the current therapeutic effect of different treatment options for elderly patients. Results The 3-year and 5-year OS rate of the 1013 elderly patients was 44.8% and 32.8%, respectively. Their median survival was 28.00 months. The median survival of patients with squamous cell carcinoma was longer than that of other pathological type (squamous vs. other types: 31.00 vs. 20.00 months, p = 0.018). The median survival of patients with surgery only or combined therapy was longer than that of radiotherapy, chemotherapy, and no therapy (surgery only vs. combined therapy vs. radiotherapy vs. chemotherapy vs. no therapy: 56.00 vs. 33.00 vs. 26.00 vs.18.00 vs. 16.00 months, p < 0.001). The 5-year OS rate of patients with highly differentiated cancer was higher than that of medium differentiated and poor differentiation/undifferentiated. In multivariate analysis, the older ages, pathological stage, were independent prognostic risk factors for poor EC survival. Treatment method was independent protective factors predictive of a good EC OS. Conclusions The survival rate of the elderly EC patients was still low in China. Age, therapy method, and pathological stage were mainly associated with the survival rate of EC in elderly patients.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2023]版:
大类 | 2 区 医学
小类 | 3 区 肿瘤学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
JCR分区:
出版当年[2023]版:
Q2 ONCOLOGY
最新[2023]版:
Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者:
第一作者机构: [1]Chinese Acad Sci, Univ Chinese Acad Sci, Zhejiang Canc Hosp,Zhejiang Key Lab Diag & Treatm, Canc Hosp,Inst Basic Med & Canc IBMC,Dept Canc Pr, Hangzhou 310022, Zhejiang, Peoples R China
通讯作者:
通讯机构: [1]Chinese Acad Sci, Univ Chinese Acad Sci, Zhejiang Canc Hosp,Zhejiang Key Lab Diag & Treatm, Canc Hosp,Inst Basic Med & Canc IBMC,Dept Canc Pr, Hangzhou 310022, Zhejiang, Peoples R China [7]Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Natl Canc Ctr, Beijing 100021, Peoples R China [*1]Department of Cancer Prevention/Zhejiang Key Laboratory of Diagnosis and Treatment Technology on Thoracic Oncology (Lung and Esophagus), The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, P.R. China [*2]National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100021, P.R. China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:39770 今日访问量:0 总访问量:1333 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号